Breakthrough Immunotherapy Extends Lives in Multiple Myeloma Patients
TL;DR Summary
A new FDA-approved treatment called Carvykti, a CAR T-cell therapy developed by Legend Biotech in New Jersey, offers a potential 'functional cure' for multiple myeloma, significantly extending remission periods and improving quality of life for patients like Carmen Phaneuf, who has managed to stay in remission for nearly three years after treatment.
- A revolutionary drug made in N.J. is giving cancer patients years of their lives back NJ.com
- Wilmot Cancer Institute’s Carvykti treatment gives hope to cancer patients WHEC.com
- FDA Approvals for Multiple Myeloma CancerNetwork
- CARTITUDE-1 Trial Shows Unprecedented 5-Year Remission in Relapsed/Refractory Multiple Myeloma: Sundar Jagannath, MBBS AJMC
- New immunotherapy for multiple myeloma shows promising results Arizona PBS
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
6 min
vs 7 min read
Condensed
96%
1,301 → 52 words
Want the full story? Read the original article
Read on NJ.com